- Home
- GRI vs IMTE Comparison
GRI vs IMTE Comparison
Compare GRI & IMTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- IMTE
- Stock Information
- Founded
- GRI 2018
- IMTE 2008
- Country
- GRI United States
- IMTE Malaysia
- Employees
- GRI N/A
- IMTE N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- IMTE Consumer Electronics/Appliances
- Sector
- GRI Health Care
- IMTE Consumer Staples
- Exchange
- GRI Nasdaq
- IMTE Nasdaq
- Market Cap
- GRI 4.3M
- IMTE 3.8M
- IPO Year
- GRI N/A
- IMTE N/A
- Fundamental
- Price
- GRI $1.64
- IMTE $0.66
- Analyst Decision
- GRI Strong Buy
- IMTE
- Analyst Count
- GRI 2
- IMTE 0
- Target Price
- GRI $22.50
- IMTE N/A
- AVG Volume (30 Days)
- GRI 175.4K
- IMTE 54.1K
- Earning Date
- GRI 11-14-2025
- IMTE 09-26-2025
- Dividend Yield
- GRI N/A
- IMTE N/A
- EPS Growth
- GRI N/A
- IMTE N/A
- EPS
- GRI N/A
- IMTE N/A
- Revenue
- GRI N/A
- IMTE $123,337.00
- Revenue This Year
- GRI N/A
- IMTE N/A
- Revenue Next Year
- GRI N/A
- IMTE N/A
- P/E Ratio
- GRI N/A
- IMTE N/A
- Revenue Growth
- GRI N/A
- IMTE 4.75
- 52 Week Low
- GRI $1.10
- IMTE $0.51
- 52 Week High
- GRI $17.51
- IMTE $3.17
- Technical
- Relative Strength Index (RSI)
- GRI 41.46
- IMTE 28.73
- Support Level
- GRI $1.60
- IMTE $0.79
- Resistance Level
- GRI $1.79
- IMTE $0.89
- Average True Range (ATR)
- GRI 0.17
- IMTE 0.09
- MACD
- GRI -0.04
- IMTE -0.02
- Stochastic Oscillator
- GRI 7.25
- IMTE 6.88
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.